Abstract:Background
The aim to develop a highly stable near-infrared (NIR) photoinduced tumor therapy agent stems from its considerable potential for biological application. Due to its long wavelength, biological imaging exhibits a high signal-to-background ratio, deep tissue penetration and maximum permissible light power, which can minimize damage to an organism during photoinduced tumor therapy.
Results
A class of stable NIR-II fluorophores (NIR998, NIR1… Show more
“…Then, the photothermal conversion efficiency of S-tBuazaBDP-NPs was calculated to be 49%, and was near to the highest one (50.5%) in aza-BODIPY system. 81 Next, in order to evaluate S-tBuazaBDP-NPs photothermal stability, we used 690 nm laser (0.8 W•cm -2 ) to irradiate dyes in aqueous solution (80 M) for 5 min, then cooling naturally, and the temperature changes were recorded during the process of heating-cooling cycles. As shown in Fig.…”
Near-infrared absorbing aza-BODIPYs with the 1,7-Di-tert-butyl groups (tBuazaBDP) were successfully synthesized for the first time. By X-ray crystal analysis, S-tBuazaBDP is more twisted than the reported dye tetraphenyl aza-BODIPY. tBuazaBDPs...
“…Then, the photothermal conversion efficiency of S-tBuazaBDP-NPs was calculated to be 49%, and was near to the highest one (50.5%) in aza-BODIPY system. 81 Next, in order to evaluate S-tBuazaBDP-NPs photothermal stability, we used 690 nm laser (0.8 W•cm -2 ) to irradiate dyes in aqueous solution (80 M) for 5 min, then cooling naturally, and the temperature changes were recorded during the process of heating-cooling cycles. As shown in Fig.…”
Near-infrared absorbing aza-BODIPYs with the 1,7-Di-tert-butyl groups (tBuazaBDP) were successfully synthesized for the first time. By X-ray crystal analysis, S-tBuazaBDP is more twisted than the reported dye tetraphenyl aza-BODIPY. tBuazaBDPs...
“…CB1 is fairly hydrophobic as are many other NIR-II fluorophores 32 and therefore DSPE-PEGylated CB1 nanoparticles were prepared by a nanoprecipitation approach. The morphology of the CB1 NPs was characterized by TEM and SEM.…”
Section: Preparation and Characterization Of The Cb1 Npsmentioning
confidence: 99%
“…[25][26][27][28] However, few of them exhibit NIR-II emission capabilities. [29][30][31][32] Herein, we report the design and preparation of a new aza-BODIPY-derived agent named CB1 with extended π-conjugation and proper structural modifications (Scheme 1). The DSPE-PEGylated CB1 nanoparticles (CB1 NPs) show a maximum emission peak at 1015 nm and are capable of in vivo NIR-II fluorescence imaging.…”
The fabrication of high-performance second near-infrared (NIR-II) biological window fluorophore is in urgent need for precise diagnosis and treatment of cancer. Nevertheless, the construction of phototherapeutic agents in the NIR-II...
“…26 Subsequently, several NIR-II aza-BODIPY fluorophores were acquired, but their fluorescence was too weak to carry out NIR-II fluorescence imaging after the photosensitizers were encapsulated into nanoparticles. 27,28 In addition, the efficiency of PDT or PTT alone is usually unsatisfactory because of the hypoxic nature of the tumor microenvironment for PDT and acquired a heat shock effect in PTT. 29 The collaboration of PTT and PDT is a good strategy to overcome the respective drawbacks to enhance treatment output because PTT could improve the oxygen supply in the tumor tissue by increasing the blood flow rate, thus promoting the PDT effect, which conversely further eliminates the heat-resistant tumor cells in PTT.…”
Fluorescence imaging in the second near-infrared window (NIR-II, 1000–1700 nm) holds great promise for in vivo imaging and imaging-guided phototherapy with deep penetration and high spatiotemporal resolution. It is very...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.